Latest Zonisamide Stories
RnRMarketResearch.com adds “Partial Seizure – Pipeline Review, H2 2014” to its store.
WOODCLIFF LAKE, N.J., Sept. 3, 2014 /PRNewswire/ -- Eisai Inc., the U.S.
LONDON, June 30, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Looks to Expand Global Epilepsy Product Portfolio Tokyo, Sept 1, 2011 - (JCN Newswire) - Eisai Co., Ltd.
HATFIELD, England, Jan. 25, 2011 /PRNewswire/ -- Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies.
HATFIELD, England, January 13, 2011 /PRNewswire-FirstCall/ -- - Epilepsy Treatment Zonegran(R) First Commercially Available Product Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters: Tokyo; President and CEO: Haruo Naito) announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam.
ATLANTA, June 29 /PRNewswire/ -- New long term data showed that VimpatÂ® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy.
SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- OrexigenÂ® Therapeutics, Inc.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.